Skip to main content

ASCO 2017 - Chronic Lymphocytic Leukemia

ASCO 2017 - Chronic Lymphocytic Leukemia
Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
COSMOS: A 2-Cohort, Phase 2 Study of MOR208 plus Idelalisib or Venetoclax in Patients with R/R CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Read More
Page 2 of 2
Results 11 - 16 of 16